Adeno-associated virus mediated interferon-gamma inhibits the progression of hepatic fibrosis in vitro and in vivo

Table 1 Primer pairs for RT-PCR used in this study

Gene	Forward primer	Reverse primer
INF-γ	5’-CCGCTCGAGATGAAATATACAAGTTATATC-3’	5’-CGGAATTCTTACTGGGATGCTCTTCGACC-3’
TGF-β	5’-CTTCAGCTCCACAGAGAAGAACTGC-3’	5’-CACGATCATGTTGGACAACTGCTCC-3’
TIMP-1	5’-CCGCAGACGGCGTTCTGCAA-3’	5’-TCGAGACCCAAGGGATTGCC-3’
MMP-13	5’-TGACTATGCGTGGCTGGAA-3’	5’-AAGCTGAAATCTTGCCTTGGA-3’
GAPDH	5’-GTCAACGGATTTGGTCGTATT-3’	5’-AGTCTTCTGGGTGGCAGTGAT-3’

Table 2 Serum markers of hepatic fibrosis and damage

	Number	Hydroxyproline	AST (U/L)	ALT (U/L)
		(µg/g wet liver)
No treatment	6	96 ± 11	76.3 ± 6.3	53.0 ± 6.9
CCl4 (3 wk)	6	162 ± 14	561.2 ± 81.4	358.0 ± 85.4
CCl4/Saline	8	236 ± 31	1 019.1 ± 276.3	770.5 ± 154.3
CCl4/rAAV-eGFP	8	249 ± 37	985.4 ± 241.6	727.2 ± 175.0
CCl4/rAAV-INF-γ	8	177 ± 281	668.5 ± 140.02	458.4 ± 123.53

Hydroxyproline content and serum AST, ALT are shown with mean ±SD for each group. There are no significant differences between group of CCl₄/saline and CCl₄/rAAV-eGFP in all three markers. The group of CCl₄/rAAV-INF-γ vs CCl₄/saline:

¹P = 0.0015;

²P = 0.0064;

³P = 0.0032.